Relationship between serum levels of VIP, but not of CGRP, and cranial autonomic parasympathetic symptoms: A study in chronic migraine patients

Cephalalgia ◽  
2016 ◽  
Vol 37 (9) ◽  
pp. 823-827 ◽  
Author(s):  
N Riesco ◽  
E Cernuda-Morollón ◽  
P Martínez-Camblor ◽  
AI Pérez-Alvarez ◽  
L Verano ◽  
...  
Keyword(s):  
Chronic Migraine ◽  
Significant Positive Correlation ◽  
Vascular System ◽  
Serum Levels ◽  
Spearman Correlation ◽  
Pain Pathways ◽  
Calcitonin Gene ◽  
Intestinal Peptides ◽  
Vasoactive Intestinal Peptides ◽  
Rate Of Activation

Background Cranial autonomic parasympathetic symptoms (CAPS) appear in at least half of migraine patients theoretically as a result of the release of peptides by the trigemino-vascular system (TVS). Cranial pain pathways become sensitised by repeated episodes of TVS activation, leading to migraine chronification. Objective The objective of this article is to correlate the presence of CAPS with serum levels of vasoactive intestinal peptides (VIP) and calcitonin gene-related peptide (CGRP). Patients and methods Patients with chronic migraine (CM) were asked about the presence – during migraine attacks – of five CAPS, which were scored from 0 to 10 by using a quantitative scale. Serum VIP and CGRP levels were determined by ELISA. Results We interviewed 87 CM patients (82 females; mean age 44.7 ± 10.6 years). Seventeen had no CAPS, while 70 reported at least one CAPS. VIP levels ranged from 20.8 to 668.2 pg/ml (mean 154.5 ± 123.2). There was a significant positive correlation between scores in the CAPS scale and VIP levels (Spearman correlation coefficient = 0.227; p = 0.035). VIP levels were significantly higher in CM patients by at least one point in the scale vs those with 0 points ( p = 0.002). Analysing symptoms individually, VIP levels were numerically higher in those patients with symptoms, though they were significantly higher only in those patients with lacrimation vs those without it ( p = 0.013). There was no significant correlation between CGRP levels and the score in the CAPS scale. Conclusions Serum VIP, but not CGRP, levels seem to reflect the rate of activation of the parasympathetic arm of the TVS in migraine.

scholarly journals Serum CGRP, VIP, and PACAP Usefulness in Migraine: A Case-Control Study in Chronic Migraine Patients in Real Clinical Practice.

2020 ◽  
Author(s):  
Sara Pérez Pereda ◽  
María Toriello-Suárez ◽  
Gonzalo Ocejo-Vinyals ◽  
Sandra Guiral-Foz ◽  
Jesús Castillo-Obeso ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Chronic Migraine ◽  
Serum Levels ◽  
Diagnostic Value ◽  
Episodic Migraine ◽  
Medical Centers ◽  
Calcitonin Gene ◽  
Multinomial Modeling ◽  
Global Accuracy ◽  
Real Clinical Practice

Abstract Background: Calcitonin gene-related peptide (CGRP), vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypetide-38 (PACAP-38) have relevant roles in migraine pathophysiology. Their serum levels have been proposed as biomarkers for migraine. Our aim was to assess their diagnostic value in real clinical practice in a cohort of chronic migraine (CM), episodic migraine (EM) and healthy controls (HC).Methods: We recruited subjects with CM, EM and HC at two medical centers. Blood samples were drawn under fasting conditions in the interictal period, immediately centrifuged and stored at -80º C. Serum levels were determined by ELISA. Neuropeptide levels, the effect of preventatives, correlations with clinical and demographic variables, and their diagnostic value were studied among clinical categories.Results: 296 age- and sex-matched subjects (101 CM, 98 EM and 97 HC) were included. All three neuropeptide serum levels were higher in CM [median and IQ for CGRP= 18.023 pg/ml (14.4-24.7); VIP= 121.732 pg/ml (48.72-186.72) and PACAP= 204.931 pg/ml (101.08-597.64)] vs EM [CGRP = 14.659 pg/ml (10.29-17.45); VIP = 75.603 pg/ml (28.722-107.10); and PACAP = 94.992 pg/ml (65.77-128.48)] and vs HC [CGRP = 13.988 pg/ml (10.095-17.87); VIP = 84.685 pg/ml (35.32-99.79), and PACAP = 103.142 pg/ml (59.42-123.97)]. Using multinomial modeling, only VIP (OR 1.011, 95% CI=1.003-1.018, p=0.005) and PACAP (OR=1.003, 95% CI=1.001-1.005, p=0.002) increased the risk for CM, but not for EM. CGRP did not predict CM or EM. This model could correctly classify only 62/101 (61.38%) of CM, 75/98 (76.53%) of EM, and 5/97 (4.12%) of HC [globally 147/296 (49.8%)]. Individually, PACAP performed the best for classifying clinical categories [global accuracy 150/296 (50.67%)]. In CM, neuropeptide levels were higher in those OnaBT-treated than in no-treated patients.Conclusions: Although interictal serum CGRP and VIP were higher in CM than both EM or HC, their utility to discriminate migraine categories was low. Contrary to other studies, PACAP serum levels were also higher in CM than in EM or HC and had more discriminative capability to distinguish CM from EM and HC. Further investigation is needed for determination technique standardization.

scholarly journals iTRAQ-Based Quantitative Proteomics Analysis of the Protective Effect of Yinchenwuling Powder on Hyperlipidemic Rats

2017 ◽  
Vol 2017 ◽  
pp. 1-12
Author(s):  
Zheyu Zhang ◽  
Wenbo Wang ◽  
Ling Jin ◽  
Xin Cao ◽  
Gonghui Jian ◽  
...  
Keyword(s):  
Quantitative Proteomics ◽  
Serum Levels ◽  
Treated Group ◽  
Research Approach ◽  
Therapeutic Effects ◽  
Proteomics Analysis ◽  
Chinese Medicine Formula ◽  
Calcitonin Gene ◽  
Proteomics Technology ◽  
Proteomics Research

Yinchenwuling powder (YCL) is an effective traditional Chinese medicine formula to modulate lipid levels. In this study, we established hyperlipidemic rat models and treated them with YCL. The serum concentrations of lipid, malondialdehyde (MDA), endothelin-1 (ET-1), and calcitonin gene-related peptide (CGRP) were measured. Adventitia-free vascular proteins between hyperlipidemic rats and YCL-treated rats were identified using iTRAQ-based quantitative proteomics research approach. Proteins with 1.3-fold difference were analyzed through bioinformatics, and proteomic results were verified by Western blot. The results showed that the serum levels of TC, TG, LDL-C, ET-1, and MDA were significantly decreased, whereas the HDL-C and CGRP levels were significantly increased in the YCL-treated group. Proteomics technology identified 4,382 proteins, and 15 proteins were selected on the basis of their expression levels and bioinformatics. Of these proteins, 2 (Adipoq and Gsta1) were upregulated and 13 (C3, C4, C6, Cfh, Cfp, C8g, C8b, Lgals1, Fndc1, Fgb, Fgg, Kng1, and ApoH) were downregulated in the YCL-treated rats. Their functions were related to immunity, inflammation, coagulation and hemostasis, oxidation and antioxidation, and lipid metabolism and transport. The validated results of ApoH were consistent with the proteomics results. This study enhanced our understanding on the therapeutic effects and mechanism of YCL on hyperlipidemia.

scholarly journals Receptor binding of guinea pig and pig vasoactive intestinal peptides by rat lung

1988 ◽  
Vol 254 (2) ◽  
pp. 613-615 ◽  
Author(s):  
S Paul ◽  
D J Volle ◽  
J Currie
Keyword(s):  
Amino Acid ◽  
Guinea Pig ◽  
Vasoactive Intestinal Peptide ◽  
Receptor Binding ◽  
Amino Acid Residues ◽  
Rat Lung ◽  
Intestinal Peptides ◽  
Peptide Hydrolases ◽  
Vasoactive Intestinal Peptides

Guinea pig vasoactive intestinal peptide (gpVIP) differs from other mammalian VIPs in four of its 28 amino acid residues. In the present study, the gpVIP displaced 125I-labelled pig VIP (pVIP) binding by rat lung membranes with 7.7-fold lower potency than pVIP. Degradation of gpVIP by rat lung membranes, assessed by radioimmunoassay and h.p.l.c., was 1.9-fold greater than that of pVIP. This difference in degradation of the two peptides was not large enough to account for the lower receptor-binding potency of gpVIP. The amino acid residues that distinguish pVIP from gpVIP are likely to contribute to the interaction of VIP with receptors and peptide hydrolases in lung membranes.

Peptide based therapy for neurological disorders

2021 ◽  
Vol 22 ◽  
Author(s):  
Asmita Yadav ◽  
Damini Pandey ◽  
Ghulam Md Ashraf ◽  
Rachana
Keyword(s):  
Neurodegenerative Diseases ◽  
Neurodegenerative Disorders ◽  
High Throughput Screening ◽  
Mitochondrial Permeability Transition ◽  
Permeability Transition ◽  
Eukaryotic Cells ◽  
Haemolytic Activity ◽  
Peptide Bonds ◽  
Intestinal Peptides ◽  
Vasoactive Intestinal Peptides

: Peptides are small molecules composed of amino acids linked together by peptide bonds. The targeted action of these peptides along with their magnificent ability to reach locations in body that are complicated to access, is being considered of tremendous potential in disease modifying therapies. Synthetic as well as natural peptides like Carnosine are currently under research for treatment of neurodegenerative disorders (NDDs). Peptide based vaccines are currently under immense research for diseases like dementia. Toxicity of peptide-based drugs tfigureowards eukaryotic cells due to their increased haemolytic activity is of major concern and this is being tackled by introducing modifications into the peptide structure. Some crucial peptide inhibitors currently in use for neurodegenerative disorders include Aβ (16-20) KLVFF for Alzheimer’s disease, NAPVSIPQ (NAP) for Parkinson’s disease, towards eukaryotic cells Vasoactive Intestinal Peptides (VIP) for Huntington’s disease, Polyglutamine Binding Peptide-1(QBP1) for Dentatorubral-paiidoluysial atrophy (DRPLA). Certain peptides are involved in inhibition of mitochondrial permeability transition (MPT) that plays a prominent part in the materialization of neurodegenerative diseases, one such example of peptides being Ba-V which is obtained from Bothrops atrox snake venom. New therapeutic peptides are being identified using bioinformatics tools like high throughput screening (HTS). These tools are being used to explore the selectivity, stability, extent of immune response and toxic side effects of peptides. Apart from neurodegenerative diseases, the potential of bioactive peptides is also being tested against cancer, diabetes and microbes. This review focuses on the recent advances in peptide therapeutics and novel peptides discovered for treatment of the NDs.

Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial

Cephalalgia ◽  
2019 ◽  
Vol 39 (9) ◽  
pp. 1075-1085 ◽  
Author(s):  
David W Dodick ◽  
Richard B Lipton ◽  
Stephen Silberstein ◽  
Peter J Goadsby ◽  
David Biondi ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Chronic Migraine ◽  
Development Program ◽  
Calcitonin Gene Related Peptide ◽  
Electronic Diary ◽  
Phase 3 ◽  
Pivotal Phase ◽  
Double Blind ◽  
Related Peptide ◽  
Calcitonin Gene

Background Calcitonin gene-related peptide plays an important role in migraine pathophysiology. We evaluated eptinezumab, an intravenous (IV) anti-calcitonin gene-related peptide monoclonal antibody, for the prevention of chronic migraine. Objective To determine the safety, tolerability, and effectiveness of four dose levels of eptinezumab and to inform the phase 3 development program. Methods This was a phase 2b, parallel-group, double-blind, randomized, placebo-controlled, dose-ranging clinical trial. Men and women (N = 616) aged 18–55 years were included if they had a diagnosis of chronic migraine, with onset at age ≤35 years and history of chronic migraine ≥1 year. During the 28-day screening period, patients must have had ≥15 headache days, including ≥8 migraine days, with ≥5 migraine attacks as recorded in the electronic diary. Patients were assigned in a 1:1:1:1:1 ratio to eptinezumab 300, 100, 30, 10 mg or placebo, administered as a single IV infusion. The primary endpoint was the percentage of patients with a ≥75% decrease in monthly migraine days over weeks 1–12 compared with the 28-day screening period. Results The ≥75% migraine responder rates over weeks 1–12 for eptinezumab 300, 100, 30, and 10 mg were 33.3%, 31.4%, 28.2%, and 26.8%, respectively, versus 20.7% for placebo ( p = 0.033, 0.072, 0.201, 0.294 vs. placebo). Secondary efficacy endpoints (e.g. ≥50% responder rate, change from baseline in frequency of migraine/headache days, and percentage of severe migraines) had results favoring the three higher eptinezumab doses versus placebo. Eptinezumab was well tolerated and adverse event rates were similar to placebo. Conclusions The results of this trial demonstrate that eptinezumab appears effective and well-tolerated for the preventive treatment of chronic migraine and justifies the conduct of pivotal phase 3 trials for migraine prevention. Trial Registration ClinicalTrials.gov identifier: NCT02275117.

Sign in / Sign up

Export Citation Format

Share Document